Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 20/20 | 1.00 |
| ▸ | F3 | P13726 | 20/20 | 1.00 |
| ▸ | KLK1 | P06870 | 1/20 | 0.74 |
| ▸ | F2 | P00734 | 1/20 | 0.74 |
| ▸ | F10 | P00742 | 1/20 | 0.74 |
| ▸ | F11 | P03951 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3080306 | 1.00 | F7 (1.00) | F7F3KLK1F2F10 | |
| SCHEMBL15259821 | 1.00 | F7 (1.00) | F7F3KLK1F2F10 | |
| SCHEMBL3068755 | 1.00 | F7 (1.00) | F7F3KLK1F2F10 | |
| SCHEMBL12220023 | 0.95 | F7 (1.00) | F7F3KLK1F2F10 | |
| SCHEMBL15259846 | 0.95 | F7 (0.90) | F7F3KLK1F2F10 | |
| SCHEMBL15259765 | 0.95 | F7 (0.90) | F7F3KLK1F2F10 | |
| SCHEMBL15268042 | 0.93 | F7 (0.87) | F7F3KLK1F2F10 | |
| SCHEMBL2528726 | 0.92 | F7 (1.00) | F7F3KLK1F2F10 | |
| SCHEMBL2528723 | 0.92 | F7 (1.00) | F7F3KLK1F2F10 | |
| SCHEMBL2525613 | 0.91 | F7 (1.00) | F7F3KLK1F2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061756-B1 | 2-AMINOCARBONYLPHENYLAMINO-2-PHENILACETAMIDES AS FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL MYERS SQUIBB CO (US) | 2013-09-25 | — | — | EP | claimed |
| EP-2061756-B1 | 2-AMINOCARBONYLPHENYLAMINO-2-PHENILACETAMIDES AS FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL MYERS SQUIBB CO (US) | 2013-09-25 | — | — | EP | disclosed |
| US-8222453-B2 | Benzamide factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222453-B2 | Benzamide factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-17 | — | — | US | disclosed |
| US-20100227894-A1 | BENZAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-09 | — | — | US | disclosed |
| US-20100227894-A1 | BENZAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227894-A1 | BENZAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F7, F9, F8 | F7 1/4885F3 10/4885KLK1 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.